USCOM LIMITED — Capital/Financing Update 2015

Nov 24, 2015

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

Uscom New SpiroSonic Series of Asthma Products

SYDNEY, Australia, Wednesday 25th November 2015: Uscom Limited (ASX code: UCM) (the Company or Uscom ), a cardiovascular and pulmonary medical devices company, today announced to the market the release of a new series of medical devices for improving diagnosis and treatment of asthma and chronic obstructive lung disease (COPD). The devices were acquired in the Thor transaction and have undergone renaming, rebranding, relabelling and repricing and are being prepared for sale in global markets over the next twelve months.

The SpiroSonic range of spirometers utilises advanced and novel ultrasound technology to accurately measure the direction, velocity and volume of airflow during inspiration and expiration. The patterns of this airflow can be used to diagnose diseases of the lungs including asthma and COPD, disease which effect 500 million patients worldwide. The devices can also be used to measure the effectiveness of asthma and COPD therapies. SpriosSonic has been trademarked by Uscom worldwide.

Disordered breathing is at the centre of sleep medicine, and these new high fidelity ultrasound devices have important potential applications in sleep medicine.

The SpiroSonic range includes 7 premium quality products; the SpiroSonic Flo, SpiroSonic Mobile, SpiroSonic Smart, SpiroSonic Pro, SpiroSonic HD, SpiroSonic Reader and Spirosonic Reporter. There are also a further 3 research products currently under clinical testing for release over the next 12 to 18 months.

The Uscom SpiroSonic digital spirometers have been designed to take research quality respirometry measurements into clinical and home care applications. The devices are FDA cleared and covered by US CPT and Australian MBS Codes for between $50 and $87 AUD, and will retail for approximately $2,000 to 3,000 AUD.

Executive Chairman of Uscom, Associate Professor Rob Phillips said, “The release of the SpiroSonic suite of digital ultrasonic spirometers has caught the attention of the spirometry market, and we have had a lot of interest in our new products at Medica in Dusseldorf last week. Our strategy has been to build a practice leading product portfolio across the vital applications of cardiac, vascular and pulmonary medicine and this is a next step. The release of the SpiroSonic range will spearhead our entry into the UK and US spirometer market, and we are currently negotiating with specialist distributors in these jurisdictions. The objective is to be generating substantial revenue from these devices within the next 12 months.”

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom Thor digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications.

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

About Uscom

Uscom Limited (UCM) is an ASX listed innovative medical technology company specialising in development and marketing of premium cardiovascular and pulmonary medical devices. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A, Uscom BP+ and the Uscom Thor Spirometers. All Uscom devices are premium quality, and deploy innovative and practice leading technologies with FDA, CE and TGA regulatory approval, and which are currently being marketed into global distribution networks.

The USCOM 1A is a simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotrope and vasoactive cardiovascular therapy.

The Uscom BP+ is a supra systolic oscillometric Central Blood Pressure monitor which measures blood pressure and blood pressure waveforms only previously available using cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, heart failure, intensive care, general practice and home care.

Uscom Thor spirometers are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide advanced pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma and monitoring pulmonary therapeutic compliance.

For more information, please visit: www.uscom.com.au Uscom Contacts

Associate Professor Rob Phillips Executive Chairman rob@uscom.com.au

Catherine Officer Company Secretary secretary@uscom.com.au